VERU

Veru Inc.
CAPPED RATING

Veru Inc is a biopharmaceutical company focused on urology and oncology. It develops prescription products for benign prostatic hyperplasia hot flashes associated with cancer treatment, male infertility and novel chemotherapies for a variety of cancers.

Veru Inc. (VERU) is rated C (2.5/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Profitability (B-); its weakest is Growth (D+).

Quantitative Factor Evaluation • Updated

Overall Rating
2.5 / 5.0
C
Value
C+
Factor Score 2.5 / 5.0
Growth
D+
Factor Score 1.5 / 5.0
Profitability
B-
Factor Score 2.9 / 5.0
Momentum
C+
Factor Score 2.8 / 5.0
Revisions
C+
Factor Score 2.6 / 5.0

Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms

Ratings of B- and above are for members.

Register free to see every rating — your first 2 weeks of Premium are on us.

Register — 2 weeks free

Underlying Financial Metrics

P/E Ratio -2.1
EV / EBITDA -0.5
Rev Growth YoY N/A
Gross Margin 0.0%
Price Return 3M -20.5%
Price Return 12M -23.4%
Catalyst Signal 0.00
Market Cap $35.6M
TTM Revenue N/A
Price / Sales N/A
ROE -64.5%

Historical Factor Score Progression

Date Value Growth Profitability Momentum Revisions Overall
2026-11-15 C+ (2.5) D+ (1.5) B- (2.9) C+ (2.8) C+ (2.6) C (2.5)
2026-11-08 C+ (2.5) D+ (1.5) B- (2.9) C+ (2.6) C+ (2.6) C (2.4)
2026-11-01 C+ (2.5) D+ (1.5) B- (2.9) B- (2.9) C+ (2.7) C+ (2.5)
2026-10-25 C+ (2.5) D+ (1.5) B- (2.9) C+ (2.6) C+ (2.6) C (2.4)
2026-10-18 C+ (2.5) D+ (1.5) B- (2.9) C+ (2.5) C+ (2.6) C (2.4)
Page 1 of 4